FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025006321> ?p ?o ?g. }

• W2025006321 endingPage "460" @default.
• W2025006321 startingPage "454" @default.
• W2025006321 abstract "Purpose To assess whether the benefits of adding cisplatin (CDDP) concurrent with radiotherapy, followed by adjuvant CDDP and fluorouracil, justifies the toxicity cost for nasopharyngeal cancer (NPC) using the quality-adjusted time without symptoms or toxicity (Q-TWiST) approach. Methods and Materials One hundred seven patients treated with radiotherapy (RT) and 111 with concurrent chemotherapy and radiotherapy (CRT) were analyzed. The overall survival was divided into three health states: time on active treatment only, during which any subjective nonhematologic toxic event of grade > = 3 was reported; time without symptoms of disease relapse; or treatment and time following first disease RELapse. The relative advantage of CRT and RT was examined by conducting the analysis cumulatively at restriction times 3, 6, 24, 36, 48 months. Results At 48 months, the improvement in disease-free survival was 14.4% for CRT, whereas that for overall survival was 18.9%. The differences in Q-TWiST were −0.4, −0.7, 0.1, 1.6, and 3.6 months at 3, 6, 24, 36, and 48 months, respectively, with positive differences favoring CRT. At 24 months, the difference in Q-TWiST began to favor CRT. At 36 months, CRT may be the preferred option from the patient's viewpoint if the time spent in the REL state is valued to be <0.83, with the value of perfect health being 1. Finally, Q-TWiST accumulated within 48 months indicated a significant advantage in quality-adjusted survival time for CRT (p = 0.020). Conclusion Irrespective of how patients valued periods of toxicity and delayed disease progression, concurrent chemotherapy and radiotherapy offered NPC patients significantly more quality-adjusted survival than radiotherapy alone in the long term. To assess whether the benefits of adding cisplatin (CDDP) concurrent with radiotherapy, followed by adjuvant CDDP and fluorouracil, justifies the toxicity cost for nasopharyngeal cancer (NPC) using the quality-adjusted time without symptoms or toxicity (Q-TWiST) approach. One hundred seven patients treated with radiotherapy (RT) and 111 with concurrent chemotherapy and radiotherapy (CRT) were analyzed. The overall survival was divided into three health states: time on active treatment only, during which any subjective nonhematologic toxic event of grade > = 3 was reported; time without symptoms of disease relapse; or treatment and time following first disease RELapse. The relative advantage of CRT and RT was examined by conducting the analysis cumulatively at restriction times 3, 6, 24, 36, 48 months. At 48 months, the improvement in disease-free survival was 14.4% for CRT, whereas that for overall survival was 18.9%. The differences in Q-TWiST were −0.4, −0.7, 0.1, 1.6, and 3.6 months at 3, 6, 24, 36, and 48 months, respectively, with positive differences favoring CRT. At 24 months, the difference in Q-TWiST began to favor CRT. At 36 months, CRT may be the preferred option from the patient's viewpoint if the time spent in the REL state is valued to be <0.83, with the value of perfect health being 1. Finally, Q-TWiST accumulated within 48 months indicated a significant advantage in quality-adjusted survival time for CRT (p = 0.020). Irrespective of how patients valued periods of toxicity and delayed disease progression, concurrent chemotherapy and radiotherapy offered NPC patients significantly more quality-adjusted survival than radiotherapy alone in the long term." @default.
• W2025006321 created "2016-06-24" @default.
• W2025006321 creator A5007205435 @default.
• W2025006321 creator A5012061252 @default.
• W2025006321 creator A5031905043 @default.
• W2025006321 creator A5090955657 @default.
• W2025006321 date "2010-10-01" @default.
• W2025006321 modified "2023-09-30" @default.
• W2025006321 title "Quality-of-Life-Adjusted Survival Analysis of Concurrent Chemo Radiotherapy for Locally Advanced (Nonmetastatic) Nasopharyngeal Cancer" @default.
• W2025006321 cites W1988921850 @default.
• W2025006321 cites W1993614797 @default.
• W2025006321 cites W2028257824 @default.
• W2025006321 cites W2028291645 @default.
• W2025006321 cites W2033521428 @default.
• W2025006321 cites W2038252730 @default.
• W2025006321 cites W2040308389 @default.
• W2025006321 cites W2092052931 @default.
• W2025006321 cites W2125919881 @default.
• W2025006321 cites W2132757216 @default.
• W2025006321 cites W2158776902 @default.
• W2025006321 cites W2160889655 @default.
• W2025006321 cites W2170430904 @default.
• W2025006321 cites W2254058470 @default.
• W2025006321 cites W2259708582 @default.
• W2025006321 cites W36655149 @default.
• W2025006321 doi "https://doi.org/10.1016/j.ijrobp.2009.07.1702" @default.
• W2025006321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20092962" @default.
• W2025006321 hasPublicationYear "2010" @default.
• W2025006321 type Work @default.
• W2025006321 sameAs 2025006321 @default.
• W2025006321 citedByCount "7" @default.
• W2025006321 countsByYear W20250063212012 @default.
• W2025006321 countsByYear W20250063212013 @default.
• W2025006321 countsByYear W20250063212014 @default.
• W2025006321 countsByYear W20250063212015 @default.
• W2025006321 countsByYear W20250063212018 @default.
• W2025006321 crossrefType "journal-article" @default.
• W2025006321 hasAuthorship W2025006321A5007205435 @default.
• W2025006321 hasAuthorship W2025006321A5012061252 @default.
• W2025006321 hasAuthorship W2025006321A5031905043 @default.
• W2025006321 hasAuthorship W2025006321A5090955657 @default.
• W2025006321 hasConcept C121608353 @default.
• W2025006321 hasConcept C126322002 @default.
• W2025006321 hasConcept C141071460 @default.
• W2025006321 hasConcept C143998085 @default.
• W2025006321 hasConcept C159110408 @default.
• W2025006321 hasConcept C2776694085 @default.
• W2025006321 hasConcept C2777863537 @default.
• W2025006321 hasConcept C2778239845 @default.
• W2025006321 hasConcept C2778424827 @default.
• W2025006321 hasConcept C2779951463 @default.
• W2025006321 hasConcept C2780456651 @default.
• W2025006321 hasConcept C29730261 @default.
• W2025006321 hasConcept C509974204 @default.
• W2025006321 hasConcept C71924100 @default.
• W2025006321 hasConceptScore W2025006321C121608353 @default.
• W2025006321 hasConceptScore W2025006321C126322002 @default.
• W2025006321 hasConceptScore W2025006321C141071460 @default.
• W2025006321 hasConceptScore W2025006321C143998085 @default.
• W2025006321 hasConceptScore W2025006321C159110408 @default.
• W2025006321 hasConceptScore W2025006321C2776694085 @default.
• W2025006321 hasConceptScore W2025006321C2777863537 @default.
• W2025006321 hasConceptScore W2025006321C2778239845 @default.
• W2025006321 hasConceptScore W2025006321C2778424827 @default.
• W2025006321 hasConceptScore W2025006321C2779951463 @default.
• W2025006321 hasConceptScore W2025006321C2780456651 @default.
• W2025006321 hasConceptScore W2025006321C29730261 @default.
• W2025006321 hasConceptScore W2025006321C509974204 @default.
• W2025006321 hasConceptScore W2025006321C71924100 @default.
• W2025006321 hasIssue "2" @default.
• W2025006321 hasLocation W20250063211 @default.
• W2025006321 hasLocation W20250063212 @default.
• W2025006321 hasOpenAccess W2025006321 @default.
• W2025006321 hasPrimaryLocation W20250063211 @default.
• W2025006321 hasRelatedWork W13394025 @default.
• W2025006321 hasRelatedWork W2363409655 @default.
• W2025006321 hasRelatedWork W2394853503 @default.
• W2025006321 hasRelatedWork W2404042595 @default.
• W2025006321 hasRelatedWork W2406263212 @default.
• W2025006321 hasRelatedWork W2408650435 @default.
• W2025006321 hasRelatedWork W2418474598 @default.
• W2025006321 hasRelatedWork W2418663701 @default.
• W2025006321 hasRelatedWork W363598932 @default.
• W2025006321 hasRelatedWork W4308718010 @default.
• W2025006321 hasVolume "78" @default.
• W2025006321 isParatext "false" @default.
• W2025006321 isRetracted "false" @default.
• W2025006321 magId "2025006321" @default.
• W2025006321 workType "article" @default.